DIHEXA

Dihexa, an angiotensin IV derivative

Dihexa is a small, modified peptide-like molecule developed at Washington State University. It was derived from angiotensin IV, a fragment of the angiotensin peptide family, and redesigned to be more stable and to cross biological barriers more readily. Its structure combines a hexanoic acid group, tyrosine, isoleucine and a 6-aminohexanoic amide, which is how it got its name.

Research interest

Dihexa has been investigated mainly for its interaction with hepatocyte growth factor (HGF) and its receptor, c-Met. In cell culture, researchers have looked at its influence on dendritic spine formation and synapse development in neurons. In rodent models, it has been studied in tasks related to learning and memory and in models of cognitive impairment. The published body of work is modest and largely from its originating group, so it remains an early-stage research compound. Its reported potency in those neuronal culture experiments is one reason it continues to appear in discussions of the HGF/c-Met system, and independent studies would help define its profile more clearly. Researchers interested in the system may also compare it with HGF itself as a positive control.

A note on terminology

Dihexa is sometimes described as a peptide and sometimes as a small molecule. Both descriptions appear in the literature; it is best thought of as a peptidomimetic, a molecule that imitates part of a peptide’s structure.

The capsule listing

Resolve offers dihexa as capsules. Each capsule contains a set amount, shown in milligrams on the label, and the container lists the total capsule count.

Lot documentation

Look for the lot number on the container and confirm it against the certificate of analysis kept in COA / Lab Reports. Reports are being uploaded batch by batch. A matching lot, compound name and per-capsule amount is what to check before any experiment begins.

Dihexa is offered for laboratory research purposes only.